EP3024841B1 - Détection de virus - Google Patents
Détection de virus Download PDFInfo
- Publication number
- EP3024841B1 EP3024841B1 EP14736939.1A EP14736939A EP3024841B1 EP 3024841 B1 EP3024841 B1 EP 3024841B1 EP 14736939 A EP14736939 A EP 14736939A EP 3024841 B1 EP3024841 B1 EP 3024841B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ligand
- moiety
- nanoparticle
- influenza virus
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims description 24
- 241000700605 Viruses Species 0.000 title description 55
- 239000002105 nanoparticle Substances 0.000 claims description 181
- 239000003446 ligand Substances 0.000 claims description 177
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 116
- 229910052737 gold Inorganic materials 0.000 claims description 114
- 239000010931 gold Substances 0.000 claims description 114
- 239000002202 Polyethylene glycol Substances 0.000 claims description 101
- 229920001223 polyethylene glycol Polymers 0.000 claims description 101
- 241000712461 unidentified influenza virus Species 0.000 claims description 81
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 59
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 57
- 239000000523 sample Substances 0.000 claims description 57
- 206010022000 influenza Diseases 0.000 claims description 42
- 125000005629 sialic acid group Chemical group 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 15
- 230000002776 aggregation Effects 0.000 claims description 13
- 238000004220 aggregation Methods 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 125000004450 alkenylene group Chemical group 0.000 claims description 9
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 229930182830 galactose Natural products 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 101710154606 Hemagglutinin Proteins 0.000 claims description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 5
- 101710176177 Protein A56 Proteins 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000000185 hemagglutinin Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 150000007970 thio esters Chemical class 0.000 claims description 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 3
- 238000006352 cycloaddition reaction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000702437 Parvovirus H3 Species 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 89
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 57
- 239000000243 solution Substances 0.000 description 50
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 38
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 19
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 19
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 19
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- 239000007787 solid Substances 0.000 description 17
- 238000010521 absorption reaction Methods 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000008033 biological extinction Effects 0.000 description 13
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 13
- 241000271566 Aves Species 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 11
- -1 phosphonate ester Chemical class 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 150000003569 thioglycosides Chemical class 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 8
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 8
- 238000004896 high resolution mass spectrometry Methods 0.000 description 8
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- NVNVPEMVTYXUHO-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCOCCOCCNC(=O)CI Chemical compound CC(C)(C)OC(=O)NCCOCCOCCNC(=O)CI NVNVPEMVTYXUHO-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 150000004702 methyl esters Chemical class 0.000 description 7
- 229930182475 S-glycoside Natural products 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- NDWKKZUXQWOXOT-UHFFFAOYSA-N CCCC(=O)N(C(=O)OC(C)(C)C)C(COCC#C)(COCC#C)COCC#C Chemical compound CCCC(=O)N(C(=O)OC(C)(C)C)C(COCC#C)(COCC#C)COCC#C NDWKKZUXQWOXOT-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 125000004185 ester group Chemical group 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- OCUICOFGFQENAS-UHFFFAOYSA-N tert-butyl n-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCOCCN OCUICOFGFQENAS-UHFFFAOYSA-N 0.000 description 5
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 4
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000003917 TEM image Methods 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 125000001033 ether group Chemical group 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 150000002454 idoses Chemical class 0.000 description 4
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 150000003214 pyranose derivatives Chemical class 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 125000006585 (C6-C10) arylene group Chemical group 0.000 description 3
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 0 CCC1OC(*)C(*)C(*)C1C Chemical compound CCC1OC(*)C(*)C(*)C1C 0.000 description 3
- KMSNYNIWEORQDJ-UHFFFAOYSA-N Dihydro-2(3H)-thiophenone Chemical compound O=C1CCCS1 KMSNYNIWEORQDJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZJVNXSHFGLQZEA-DRRXZNNHSA-N [(2r,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-(3-azidopropoxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OCCCN=[N+]=[N-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O ZJVNXSHFGLQZEA-DRRXZNNHSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002122 magnetic nanoparticle Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000000101 thioether group Chemical group 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- MUZIZEZCKKMZRT-UHFFFAOYSA-N 1,2-dithiolane Chemical compound C1CSSC1 MUZIZEZCKKMZRT-UHFFFAOYSA-N 0.000 description 2
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 2
- JCORXJUUSVCJEP-UHFFFAOYSA-N 6-azidohexanoic acid Chemical compound OC(=O)CCCCCN=[N+]=[N-] JCORXJUUSVCJEP-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 2
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- NYWZBRWKDRMPAS-GRRZBWEESA-N N-acetyl-9-O-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)COC(C)=O NYWZBRWKDRMPAS-GRRZBWEESA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-JAJWTYFOSA-N N-acetyl-beta-D-galactosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-JAJWTYFOSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 2
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229920001940 conductive polymer Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002082 metal nanoparticle Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920006295 polythiol Polymers 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- QBVXKDJEZKEASM-UHFFFAOYSA-M tetraoctylammonium bromide Chemical compound [Br-].CCCCCCCC[N+](CCCCCCCC)(CCCCCCCC)CCCCCCCC QBVXKDJEZKEASM-UHFFFAOYSA-M 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- RBNSZWOCWHGHMR-UHFFFAOYSA-N (2-iodoacetyl) 2-iodoacetate Chemical compound ICC(=O)OC(=O)CI RBNSZWOCWHGHMR-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- INWOAUUPYIXDHN-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CCCC(C(O)=O)NC(=O)OC(C)(C)C INWOAUUPYIXDHN-UHFFFAOYSA-N 0.000 description 1
- CFPHMAVQAJGVPV-UHFFFAOYSA-N 2-sulfanylbutanoic acid Chemical class CCC(S)C(O)=O CFPHMAVQAJGVPV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BJOZNDRNJJZHPZ-LUWBGTNYSA-N 9-O-acetylneuraminic acid Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1N BJOZNDRNJJZHPZ-LUWBGTNYSA-N 0.000 description 1
- 229910001316 Ag alloy Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229910001020 Au alloy Inorganic materials 0.000 description 1
- NXJQPJPNBKCBEP-UHFFFAOYSA-N C(CCCC)(=O)O.C(=O)(OC(C)(C)C)NC(C(=O)O)CCC Chemical compound C(CCCC)(=O)O.C(=O)(OC(C)(C)C)NC(C(=O)O)CCC NXJQPJPNBKCBEP-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004042 HAuCl4 Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-PVFLNQBWSA-N N-acetyl-alpha-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-PVFLNQBWSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 1
- PBZBEOMMBYNXNA-DRRXZNNHSA-N [(2R,3S,4S,5R,6R)-3,4,5-triacetyloxy-6-(3-aminopropoxy)oxan-2-yl]methyl acetate Chemical compound C(C)(=O)O[C@H]1[C@H](OCCCN)O[C@@H]([C@@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O PBZBEOMMBYNXNA-DRRXZNNHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001312 aldohexoses Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- VZDYWEUILIUIDF-UHFFFAOYSA-J cerium(4+);disulfate Chemical compound [Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VZDYWEUILIUIDF-UHFFFAOYSA-J 0.000 description 1
- 229910000355 cerium(IV) sulfate Inorganic materials 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003353 gold alloy Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- WOQPIIAJLDWJCH-UHFFFAOYSA-N oxolane-2-thione Chemical compound S=C1CCCO1 WOQPIIAJLDWJCH-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910001112 rose gold Inorganic materials 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- XHJZXCYPSJOWPV-UHFFFAOYSA-N sulfanyl ethanesulfonate Chemical compound CCS(=O)(=O)OS XHJZXCYPSJOWPV-UHFFFAOYSA-N 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Definitions
- the present invention relates generally to methods and materials for use in the detection of influenza viruses.
- the influenza virus has two types of surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA).
- the HA recognizes sialic acids present on the surface of host cells and binds to these carbohydrates in order to infect the cell and the NA releases progeny virus from the infected cell.
- Measures to prevent a new influenza virus pandemic involve both vaccination and antiviral drugs, the latter ideally administered within 48 h of the infection.
- influenza The effective use of antivirals requires rapid and early diagnosis.
- Current methods for the detection of influenza include: molecular identification of influenza isolates including reverse-transcription PCR, immunofluorescence antibody staining, virus isolation in cell culture or in embryonated chicken eggs, and serological diagnosis by haemagglutination inhibition or by microneutralization. [3b] All of these methods are time-consuming, taking several hours or even days for results to be obtained, and also require specialist equipment and trained analysts.
- Gold nanoparticles (ca. 16 nm in diameter) in aqueous suspension exhibit an intense red color due to their surface plasmon absorption band. This optical property is distance-dependent and upon aggregation of the metal nanoparticles the solution changes color. The color change, readily observed with the naked eye, is due to the coupling interactions between the surface plasmon fields of the particles.
- Gold nanoparticle-based colorimetric assays have been reported [4] for the detection of a variety of species, including oligonucleotides, metal ions, anions, small organic molecules and proteins, a field reviewed recently by Rotello et a / ..
- glyconanoparticles By functionalizing metal nanoparticles with specifically synthesized carbohydrate ligands, glyconanoparticles can be created. [6] Glyconanoparticle-based colorimetric assays have been used for for the detection of lectins, calcium ions, and cholera toxin. [7]
- Gold nanoparticles have been used for the inhibition of influenza virus.
- Papp et al. employed 14 nm gold nanoparticles functionalized with a sialic-acid-terminated glycerol dendron to inhibit X31 influenza virus (a reassortant H3N2 influenza virus carrying the HA and NA genes of A/Aichi/2/68).
- gold nanoparticles coated with a phosphonate ester analogue of the influenza therapeutic Oseltamivir, [9] with mercaptoethanesulfonate and mercaptosuccinic acid, [10] and gold nanorods functionalized with ssRNA [11] have also been used for the inhibition of influenza virus.
- Gold nanoparticles have also been used for the detection of influenza virus.
- Influenza A/Puerto Rico/8/34 (PR8) (H1N1) virus has been detected using antibody-functionalized gold nanoparticles and dynamic light scattering.
- Gold nanoparticles functionalized with a chemically unmodified monomer of sialic acid have been used to colorimetrically detect influenza B viruses of the B/Victoria and B/Yamagata lineages through the interaction between the sialic acid and the HA on the virus.
- US 2008/0194801 relates to a reportedly novel library of compounds comprising a spacer with an attachment element on one terminus and a recognition element on the other terminus.
- the library of compounds can be attached to a solid support and used in sensors and biosensors.
- WO 2011/130332 relates to glycan arrays that bind specific target HAs and are reported to detect and distinguish between various sub-types and strains of influenza virus. Methods for using the glycan arrays with assays using nanoparticle amplification technique are also reportedly disclosed.
- WO2008/123844 relates to a method and system for detecting magnetic nanoparticles include measuring a magneto-optical enhancement of TP the plasmon absorption in the optical response.
- US 2012/0015344 relates to a particulate composition formed from a conductive polymer bound to magnetic nanoparticles.
- the particulate composition can be formed into a biologically enhanced, electrically active magnetic (BEAM) nanoparticle composition by further including a binding pair member (e.g., an antibody or a fragment thereof that specifically recognizes a virus strain or a virus surface protein) bound to the conductive polymer of the particulate composition.
- a binding pair member e.g., an antibody or a fragment thereof that specifically recognizes a virus strain or a virus surface protein
- glyconanoparticles which include a novel glycoconjugate which presents an influenza-specific sialic acid moieity that can discriminate between influenza virus strains by virtue of its structure and the sialic acid linkage specificity of the corresponding HAs. These glyconanoparticles can be used to specifically and rapidly detect influenza viruses.
- Preferred glycoconjugates are trivalent, which format provides improved binding and specificity properties, and may better interact with the HA [15] .
- the inventors have demonstrated that ligands which present a sialic acid ⁇ 2,6 galactose recognition group can be used to specifically detect human influenza virus. In other embodiments sialic acid ⁇ 2,3 galactose sequences may be used to preferentially bind avian influenza virus [14] .
- the invention therefore provides a nanoparticle probe and a method for detecting influenza virus, as well as a process for preparing a nanoparticle probe, and a kit.
- a nanoparticle probe comprising a plurality of glycoconjugate ligands, each glycoconjugate ligand (GL) having a plurality of sialic acid containing recognition groups (Y) coupled to the nanoparticle via a multivalent core (X), wherein the multivalent core (X) is a trivalent core, whereby there are 3 recognition groups per ligand, wherein the recognition groups on the bioconjugate specifically bind to the hemagglutinin on the target influenza virus, wherein the probe has at least one further type of ligand bound to the nanoparticle, wherein the further type of ligand is a polyethylene glycol (PEG) which does not bind specifically to an influenza virus, wherein each recognition group terminates with the ⁇ -anomer of a sialic acid moiety, and the sialic acid moiety is bound to a monosaccharide through either:
- a target influenza virus in a sample which method comprises:
- the target influenza virus is a human influenza virus
- the signal generated in (c) is different to the signal generated by an avian influenza virus.
- other specificities may be provided as described below.
- “Different” in this context means readily distinguishable under the conditions used in (c) e.g. when compared using equivalent samples under comparable conditions.
- the signal generated by the non-target influenza virus is less than ⁇ 50%, 40%, 30%, 20%, 10%, 5% of the signal generated by the target virus.
- “Signal” in this context relates to the changes (shift or intensity) of the surface plasmon absorption band. As shown in the Examples below, preferred nanoparticle probes specific for human influenza virus (tested using X31) target showed negligible changes in the plasmonic signal in the presence of an avian virus.
- Each glycoconjugate ligand comprises a trivalent core, whereby there are 3 recognition groups (Y) per ligand.
- each glycoconjugate ligand (GL) may be of the formula: wherein: Y is a sialic-acid containing recognition group;
- Y terminates with the ⁇ -anomer of a sialic acid moiety, and the sialic acid moiety is bound to a pyranose monosaccharide unit (e.g., galactose) through a 2,6 glycosidic bond.
- a pyranose monosaccharide unit e.g., galactose
- the sialic acid moiety and monosaccharide are thio linked.
- Y may further comprise a spacer moiety 'Z' which connects the sialic acid containing moiety to the core group X.
- This may comprise, for example, an alkylene or alkenylene group which may include amine, amide, ether, ester or thioester linkages, and optionally be interrupted by one or more heteroatoms and/or rings, including aromatic rings (e.g. benzene, pyridine or 1,2,3-triazole), which rings are optionally substituted.
- m ⁇ 1 e.g. 3.
- X is a preferably multivalent core moiety; this spaces group Y from the particle, and spaces the sialic-acid moieties in Y apart to optimise binding; X may comprise groups as defined in 'Z'. It may comprise a multivalent carbon atom ("tripodal core") to which three Y recognition groups are linked (e.g. via X L groups):
- X L1 , X L2 and X L3 may be, for example, -CH 2 -O-CH 2 -.
- anomeric centre of the sialic acid moiety or moieties of the Y groups are separated from the single multivalent core carbon atom by 20 to 30 bond lengths (e.g., 22 to 25 bond lengths) or 1.5 to 3 nm (e.g., 2 to 2.5 nm).
- L is a linking moiety e.g. a thiolinkage; this facilitates attachment of the GL to the nanoparticle.
- Nanoparticles useful in the practice of the invention include those known in the art for use in other nanoparticle probes and will be made of metal (e.g., gold, silver, platinum, cobalt), semiconductor (e.g., Si, CdSe, CdS, and CdS or CdSe coated with ZnS), core shell particles (e.g., gold coated silver particles), alloy particles (e.g. silver and gold alloy), magnetic (e.g., cobalt), and non-metallic (e.g. silicon) colloidal materials.
- Core shell particles are described in PCT applications PCT/US01/50825 , and PCT/US02/16382 , as well as in U.S. patent numbers 7,147,687 and 7,238,172 .
- Other nanoparticles composed of materials e.g. that have an affinity for thiol groups may also be used.
- the nanoparticle is preferably a gold nanoparticle.
- the size of the nanoparticles is preferably from about 5 nm to about 150 nm (mean diameter), more preferably from about 5 to about 50 nm, most preferably from about 10 to about 30 nm.
- the diameter of the nanoparticle may be, for example, 3 nm or greater, 3.5 nm or greater, 4 nm or greater, or 4.5 nm or greater.
- the diameter of the nanoparticle may be, for example, 10 nm or less, 15 nm or less, 20 nm or less, 30 nm or less, 40 nm or less, 50 nm or less, 75 nm or less, 100 nm or less.
- the gold nanoparticle may have a diameter in the range of, for example, 3.5 nm to 15 nm, 3.5 to 20 nm, 3.5 to 40 nm, 3.5 nm to 50 nm, 3.5 nm to 75 nm, 3.5 nm to 100 nm.
- a preferred diameter is c.16nm e.g. 12, 13, 14, 15, 16, 17, 18, 19, or 20 nm.
- the nanoparticle is a gold nanoparticle of around 16nm diameter.
- Each nanoparticle probe will generally have multiple glycoconjugate ligands attached, spread over the surface of the nanoparticle.
- the mean number of GL compounds per nanoparticle may be 5, 10, 25, 50, 100, or 200.
- the probe has at least one further type of ligand bound to the nanoparticle, in addition to the glycoconjugate ligands, wherein the further type of ligand is one which does not bind specifically to influenza virus, and which may be used to modulate density of the glycoconjugate ligand on the surface of the nanoparticle to optimise binding and specificity.
- the probe comprises polyethylene glycol (PEG), e.g. a thiolated PEG, bound to the solid support.
- the polyethylene glycol is H(OCH 2 ) 4 S-, bound to the nanoparticle through the sulphur atom.
- the probe comprises a phase transfer reagent bound to the solid support.
- the phase transfer reagent is tetraoctylammonium halide, e.g., tetraoctylammonium bromide (TOAB)
- TOAB tetraoctylammonium bromide
- the molar ratio of glycoconjugate ligand: further ligand is between 10:90 and 90:10.
- the further ligand is in excess.
- Example ratios as disclosed herein are 1:99; 5:95; 10:90; 25:75; 50:50; 75:25: or 90:10.
- the ratio of glycoconjugate ligand: further ligand is between 15:85 and 35:65 e.g. between 20:80 and 30:70 e.g. about 25:75.
- the detectable signal is a color change, which may be observable with the naked eye.
- step (b) causes aggregation of the nanoparticles, wherein said aggregation generates or contributes to the detectable plasmonic signal.
- the detectable signal is generated within 60, 50, 40, 30, 20, 10 or 5 mins.
- the methods of the present invention can be used with little or no sample preparation. They can be used, for example, for detecting influenza viruses and/or virus particles in samples of animals and/or humans like swabs, faeces and blood, in environmental samples. In one embodiment, the methods of the present invention are used for detecting influenza viruses and/or virus particles in sputum or saliva samples of animals and/or humans.
- the nanoparticle probes are utilised in an aqueous suspension.
- a virus-detection solution comprising an aqueous suspension of a glycoconjugate described above, bound to nanoparticles.
- concentration of glycoconjugate-covered nanoparticles in the virus-detection solution may be 0.05 nM to 10 nM, for example, 0.1 nM to 7.0 nM, or 1 nM to 5 nM.
- a sample of interest may be added directly (neat) to the virus-detection solution.
- a sample of interest may be diluted prior to being added to the virus-detection solution.
- a detectable plasmonic signal e.g. color change
- a detectable plasmonic signal e.g. color change
- Such an assessment with the naked eye can be made more readily against a background of a contrasting color.
- the observation of a color change is facilitated by spotting a sample of the hybridization solution on a solid white surface (such as silica or alumina TLC plates, filter paper, cellulose nitrate membranes, and nylon membranes, preferably a nylon membrane) and allowing the spot to dry.
- a solid white surface such as silica or alumina TLC plates, filter paper, cellulose nitrate membranes, and nylon membranes, preferably a nylon membrane
- the color change may be quantitated by recording the plate image with an optical scanning device such as a flatbed scanner or CCD camera, and analyzing the amount and type of color of each individual spot.
- an optical scanning device such as a flatbed scanner or CCD camera
- a color filter e.g. red filter
- Suitable substrates include transparent solid surfaces (e.g., glass, quartz, plastics and other polymers), opaque solid surface (e.g., white solid surfaces, such as TLC silica plates, filter paper, glass fiber filters, cellulose nitrate membranes, nylon membranes), and conducting solid surfaces (e.g., indium-tin-oxide (ITO)).
- transparent solid surfaces e.g., glass, quartz, plastics and other polymers
- opaque solid surface e.g., white solid surfaces, such as TLC silica plates, filter paper, glass fiber filters, cellulose nitrate membranes, nylon membranes
- conducting solid surfaces e.g., indium-tin-oxide (ITO)
- the substrate can be any shape or thickness, but generally will be flat and thin.
- transparent substrates such as glass (e.g., glass slides) or plastics (e.g., wells of microtiter plates).
- samples may be subject to confirmatory tests like reverse transcription polymerase chain reaction.
- the glycoconjugate ligands can be attached to different (non-nanoparticle) solid supports.
- solid support refers to a material having a rigid or semi-rigid surface which a compound as described herein can bond to. Such supports will preferably take the form of small beads, pins/crowns, laminar surfaces, pellets, disks.
- the solid support may be part of detection system e.g. based on surface plasmon resonance, or surface enhanced Raman spectroscopy.
- the glycoconjugate ligands can be attached to a fluorescent nanoparticle, e.g., a quantum dot, a fluorescently-tagged polymer bead, a fluorescently-tagged silica bead (e.g., silica nanoparticle) or a fluorescently-tagged magnetic bead (e.g., magnetic nanoparticle).
- a fluorescent nanoparticle e.g., a quantum dot
- a fluorescently-tagged polymer bead e.g., a fluorescently-tagged silica bead (e.g., silica nanoparticle) or a fluorescently-tagged magnetic bead (e.g., magnetic nanoparticle).
- nanoparticle probes as described herein comprise:
- the recognition group (Y) on the bioconjugate specifically binds to the hemagglutinin on a target influenza virus, which specific binding generates a detectable plasmonic signal which is specific to the influenza virus.
- the nanoparticle probes comprise a glycoconjugate ligand (GL) attached to a nanoparticle, wherein each GL compound comprises 1 or more, preferably 2, most preferably 3 sialic-acid containing recognition groups (Y), as shown in of formula (I):
- the GL may be of the formula (II): wherein:
- m is 3 to 6.
- m is 3 to 5.
- m is 3 or 4.
- m is 3.
- the sialic-acid containing recognition group, Y comprises a sialic acid moiety attached to one or more monosaccharide units, with the monosaccharide units being attached to the core, X, by a bond or by a spacer moiety.
- Y terminates with the ⁇ -anomer of a sialic acid moiety, and the sialic acid moiety is bound to a pyranose monosaccharide unit (e.g., galactose) through a 2,3 glycosidic bond.
- a pyranose monosaccharide unit e.g., galactose
- Y terminates with the ⁇ -anomer of a sialic acid moiety, and the sialic acid moiety is bound to a pyranose monosaccharide unit (e.g., galactose) through a 2,6 glycosidic bond.
- a pyranose monosaccharide unit e.g., galactose
- the anomeric centre of the sialic acid moiety is separated from the multivalent centre of the core moiety X by 20 to 30 bond lengths (e.g., 22 to 25 bond lengths). This is described in more detail hereinafter.
- the anomeric centre of the sialic acid moiety is separated from the core moiety X by 1.5 to 3 nm (e.g., 2 to 2.5 nm).
- each sialic-acid containing recognition group Y is independently a moiety of the following formula: wherein:
- Y has a relative molecular weight of less than 5,000.
- Y has a relative molecular weight of less than 3,000.
- Y has a relative molecular weight of less than 2,000.
- Y has a relative molecular weight of less than 1,000.
- each core moiety, X is attached to more than one type of sialic-acid containing recognition group, Y (e.g., sialic-acid containing recognition groups with different Sia, Sac 1 , Sac N , Z and or n).
- Y e.g., sialic-acid containing recognition groups with different Sia, Sac 1 , Sac N , Z and or n.
- the GL compound may have two different types of sialic-acid containing recognition group: Y 1 and Y 2 , or three different types of sialic-acid containing recognition group: Y 1 , Y 2 and Y 3 .
- each core moiety, X is attached to only one type of sialic-acid containing recognition group, Y (i.e., all recognition groups have the same Sia, Sac 1 , Sac N , Z and n).
- sialic acid moiety is a moiety which is related to neuraminic acid, which has the following formula:
- sialic acid moiety is a moiety of the following formula: or a salt thereof; wherein:
- C 1-6 alkyl as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a saturated hydrocarbon compound having from 1 to 6 carbon atoms. For groups with more than 3 carbon atoms, the group can be linear or branched.
- the sialic acid moiety is a moiety of the following formula: or a salt thereof; wherein:
- Examples of suitable moieties of formulae (V) and (VI) include, for example, the moieties shown in Table I.
- Table I Examples of sialic acid moieties falling within formulae (V) and (VI) Name Abbreviation Formula Formula Reference N -acetylneuraminic acid Neu5Ac (Sia-1) N- glycolylneuraminic acid Neu5Gc (Sia-2) N -acetyl-9- O- acetylneuraminic acid 9- O -acetyl Neu5Ac (Sia-3)
- Sia is a moiety of formula (Sia-1), (Sia-2), or (Sia-3).
- Sia is a moiety of formula (Sia-1) or (Sia-2).
- Sia is a moiety of formula (Sia-1).
- Sia moiety of formula (V) above has at least six chiral centres, specifically, the carbon atoms marked with an asterisk (*) in the following formula. Each of the carbon atoms at these positions may be in either ( R ) or ( S ) configuration. Unless otherwise stated, a reference to one enantiomer/diastereomer is intended to be a reference to both enantiomers/all diasteromers.
- sialic acid moiety is of the following formula:
- the R C2 group e.g., COOR 1
- the R C2 group is in the axial position.
- the R C2 group e.g., COOR 1
- the R C2 group is in the equatorial position.
- the sialic acid moiety Sia is the ⁇ -anomer.
- the sialic acid moiety Sia is the ⁇ -anomer of a compound of formula (VI); that is, a moiety of formula (IX),
- sialic moieties falling within formula (IX) include, for example, the moieties shown in Table II.
- Table II - Examples of sialic acid moieties falling within formula (IX) Name Abbreviation Formula Formula Reference N -acetylneuraminic acid Neu5Ac (Sia-1a) N -glycolylneuraminic acid Neu5Gc (Sia-2a) N -acetyl-9- O- acetylneuraminic acid 9- O -acetyl Neu5Ac (Sia-3a)
- Sia is a moiety of formula (Sia-1a), (Sia-2a), or (Sia-3a).
- Sia is a moiety of formula (Sia-1a) or (Sia-2a).
- Sia is a moiety of formula (Sia-1a).
- Sia is a moiety of the following formula
- Sia is a moiety of the following formula:
- W is S.
- W is C.
- R C4 is OR 4 .
- R C4 is NR N4 R N5 .
- R 1 is H.
- R 1 is R A1 .
- R 4 is H.
- R 4 is R A4 .
- R 7 is H.
- R 7 is R A7 .
- R 8 is H.
- R 8 is R A8 .
- R 9 is H.
- R 9 is R A9 .
- R N4 is H.
- R N4 is C 1-6 alkyl.
- R N4 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R N4 is methyl, ethyl, i -propyl, or n -propyl.
- R N4 is methyl or ethyl.
- R N4 is methyl
- R N5 is H.
- R N5 is C 1-6 alkyl.
- R N5 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R N5 is methyl, ethyl, i -propyl, or n -propyl.
- R N5 is methyl or ethyl.
- R N5 is methyl
- R A1 is C 1-6 alkyl.
- R A1 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R A1 is methyl, ethyl, i -propyl, or n -propyl.
- R A1 is methyl or ethyl.
- R A1 is methyl
- R A4 is C 1-6 alkyl.
- R A4 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R A4 is methyl, ethyl, i -propyl, or n -propyl.
- R A4 is methyl or ethyl.
- R A4 is methyl
- R A7 is C 1-6 alkyl.
- R A7 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R A7 is methyl, ethyl, i -propyl, or n -propyl.
- R A7 is methyl or ethyl.
- R A7 is methyl
- R A8 is C 1-6 alkyl.
- R A8 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R A8 is methyl, ethyl, i -propyl, or n -propyl.
- R A8 is methyl or ethyl.
- R A8 is methyl
- R A9 is C 1-6 alkyl.
- R A9 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R A9 is methyl, ethyl, i -propyl, or n -propyl.
- R A9 is methyl or ethyl.
- R A9 is methyl
- R P1 is C 1-6 alkyl.
- R P1 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R P1 is methyl, ethyl, i -propyl, or n -propyl.
- R P1 is methyl or ethyl.
- R P1 is methyl
- R P2 is C 1-6 alkyl.
- R P2 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R P2 is methyl, ethyl, i -propyl, or n -propyl.
- R P2 is methyl or ethyl.
- R P2 is methyl
- R S1 is C 1-6 alkyl.
- R S1 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R S1 is methyl, ethyl, i -propyl, or n -propyl.
- R S1 is methyl or ethyl.
- R S1 is methyl
- R N1 is H.
- R N1 is C 1-6 alkyl.
- R N1 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R N1 is methyl, ethyl, i -propyl, or n -propyl.
- R N1 is methyl or ethyl.
- R N1 is methyl
- R N2 is H.
- R N2 is C 1-6 alkyl.
- R N2 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R N2 is methyl, ethyl, i -propyl, or n -propyl.
- R N2 is methyl or ethyl.
- R N2 is methyl
- R NN2 is C 1-6 alkyl.
- R NN2 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R NN2 is methyl, ethyl, i -propyl, or n -propyl.
- R NN2 is methyl or ethyl.
- R NN2 is methyl
- R NN2 is CH 2 OR NNN2 .
- R NNN2 is H.
- R NNN2 is R NNNN2 .
- R NNNN2 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R NNNN2 is methyl, ethyl, i -propyl, or n -propyl.
- R NNNN2 is methyl or ethyl.
- R NNNN2 is methyl
- the sialic acid moiety, Sia is attached to a monosaccharide unit, Sac 1 , which is a pyranose-based monosaccharide.
- the monosaccharide unit Sac 1 is a compound of the following formula: wherein;
- this monosaccharide unit can exist in two anomeric forms, designated alpha ( ⁇ ) and beta ( ⁇ ).
- alpha anomeric form the R Q1 attached to anomeric carbon C-1 is cis to the group attached to C-5.
- beta anomeric form R Q1 attached to anomeric carbon C-1 is trans to the group attached to C-5.
- Sac 1 moiety of formula (XIII) above has at least five chiral centres, specifically, the carbon atoms at positions 1, 2, 3, 4, and 5, which are each marked with an asterisk (*) in the following formula.
- Each of the carbon atoms at these positions may be in either ( R ) or ( S ) configuration.
- a reference to one enantiomer/diastereomer is intended to be a reference to both enantiomers/all diasteromers.
- Suitable monosaccharide units include pyranose forms of, for example:
- Sac 1 is a D-galactose unit.
- Sac 1 has the following formula:
- Sac 1 is the ⁇ -anomoer of a galactose unit.
- the monosaccharide unit Sac 1 is bonded to group W of the sialic acid moiety through a glycosidic bond.
- W is S
- W this corresponds to an S-glycosidic bond.
- W is C
- any of groups R Q1 , R Q2 , R Q3 , R Q4 , and R Q6 can be a bond to group W of the sialic acid moiety, as shown in Table III.
- R Q1 is a bond to W of the sialic acid moiety.
- R Q1 is R'.
- R Q1 is OR'.
- R Q1 is OR QQ1 .
- R Q2 is a bond to W of the sialic acid moiety.
- R Q2 is R'.
- R Q2 is OR'.
- R Q2 is OR QQ2 .
- R Q3 is a bond to W of the sialic acid moiety.
- Sac 1 is a D-galactose unit linked to Sia through a 2,3 bond.
- Sac 1 has the following formula: where indicates the point of attachment to W of Sia.
- Sac 1 is a D-galactose unit linked to Sia through an ⁇ -2,3 bond.
- Sia is an ⁇ -anomer, and is bonded to a D-galactose unit through a 2,3 glycosidic bond.
- Sia-Sac 1 are of the following formula:
- the D-galactose unit is the ⁇ -anomer.
- R Q3 is R'.
- R Q3 is OR'.
- R Q3 is OR QQ3 .
- R Q4 is a bond to W of the sialic acid moiety.
- R Q4 is R'.
- R Q4 is OR'.
- R Q4 is OR QQ4 .
- R Q6 is a bond to W of the sialic acid moiety.
- Sac 1 is a D-galactose unit linked to Sia through a 2,6 bond.
- Sac 1 has the following formula: where indictates the point of attachment to W of Sia.
- Sac 1 is a D-galactose unit linked to Sia through an ⁇ -2,6 bond.
- Sia is an ⁇ -anomer, and is bonded to a D-galactose unit through a 2,6 glycosidic bond.
- Sia-Sac 1 are of the following formula:
- the D-galactose unit is the ⁇ -anomer.
- R Q6 is R'.
- R Q6 is OR'.
- R Q6 is OR QQ6 .
- R QQ1 is H.
- R QQ1 is R QQQ1 .
- R QQ2 is H.
- R QQ2 is R QQQ2 .
- R QQ3 is H.
- R QQ3 is R QQQ3 .
- R QQ4 is H.
- R QQ4 is R QQQ4 .
- R QQ6 is H.
- R QQ6 is R QQQ6 .
- R QQQ1 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R QQQ1 is methyl, ethyl, i -propyl, or n -propyl.
- R QQQ1 is methyl or ethyl.
- R QQQ1 is methyl
- R QQQ2 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R QQQ2 is methyl, ethyl, i -propyl, or n -propyl.
- R QQQ2 is methyl or ethyl.
- R QQQ2 is methyl
- R QQQ3 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R QQQ3 is methyl, ethyl, i -propyl, or n -propyl.
- R QQQ3 is methyl or ethyl.
- R QQQ3 is methyl
- R QQQ4 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R QQQ4 is methyl, ethyl, i -propyl, or n -propyl.
- R QQQ4 is methyl or ethyl.
- R QQQ4 is methyl
- R QQQ6 is methyl, ethyl, i -propyl, n -propyl, t -butyl, i -butyl, s -butyl or n- butyl.
- R QQQ6 is methyl, ethyl, i -propyl, or n -propyl.
- R QQQ6 is methyl or ethyl.
- R QQQ6 is methyl
- the compound may include additional monosaccharide units, Sac N , in addition to the sialic-acid-attached monosaccharide unit, Sac 1 .
- the number of Sac N units present is determined by the integer n.
- n is 0 to 10.
- n is 0 to 8.
- n is 0 to 6.
- n is 0 to 5.
- n is 0 to 4.
- n is 0 to 3.
- n is 0 to 2.
- n is 0 or 1.
- n is 0 (i.e., no Sac N are present).
- n ⁇ 1 i.e., one or more Sac N are present.
- n may be 1 to 10, 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2.
- n is 1 (i.e., one Sac N unit is present). In such an embodiment, Sac 1 and Sac N form a disaccharide.
- Suitable monosaccharide units include pyranose forms of, for example:
- Sac N is selected from one of the monosaccharide units shown in Table IV: Table IV - Suitable Sac N units Name Abbreviation Formula Formula Reference D-galactose Gal (Sac-1) ⁇ -D-galactose ⁇ -Gal (Sac-1a) ⁇ -D-galactose ⁇ -Gal (Sac-1b) D-glucose Glc (Sac-2) ⁇ -D-glucose ⁇ -Glc (Sac-2a) ⁇ -D-glucose ⁇ -Glc (Sac-2b)
- Sac 1 is bound to a monosaccharide unit of formula (Sac-2b).
- Z is a single bond.
- Z is a spacer moiety.
- the spacer moiety allows the length, composition and rigidity of the sialic-acid containing recognition group, Y to be modified. This permits the sialic-acid containing recognition groups to be presented to the binding sites of haemagglutinin whilst minimising strain in the glycoconjugate ligand compound.
- Z is a C 1-20 alkylene group (e.g., a C 1-15 or C 1-10 alkylene group).
- C 1-20 alkylene refers to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a saturated hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic.
- the alkylene group is a linear aliphatic alkylene group.
- Z is a C 1-20 alkenylene group having 1 to 3 carbon-carbon double bonds (e.g., a C 1-15 or C 1-10 alkenylene group).
- C 1-20 alkenylene having 1 to 3 carbon-carbon double bonds pertains to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified) and one to three carbon-carbon double bonds, which may be aliphatic or alicyclic.
- Z is a C 1-20 alkynylene group having 1 to 3 carbon-carbon triple bonds (e.g., a C 1-15 or C 1-10 alkynylene group).
- C 1-20 alkynylene having 1 to 3 carbon-carbon double bonds pertains to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified) and one to three carbon-carbon triple bonds, which may be aliphatic or alicyclic.
- the Z groups may optionally include one or more amine, amide, ether, ester or thioester linkages.
- the Z groups above may be optionally interrupted by one or more heteroatoms and/or aromatic rings (e.g. benzene, pyridine, or 1,2,3-triazole) which rings are optionally substituted.
- aromatic rings e.g. benzene, pyridine, or 1,2,3-triazole
- Z comprises an alkylene or alkenylene group which optionally includes one or more amine, amide, ether, ester or thioester linkages, and optionally is interrupted by one or more heteroatoms (e.g., O, S, N) and/or aromatic rings (e.g., pyridine, benzene, 1,2,3-triazole).
- heteroatoms e.g., O, S, N
- aromatic rings e.g., pyridine, benzene, 1,2,3-triazole
- Z comprises a triazole group.
- Z comprises an amide linkage
- Z is a C 1-20 amine group (e.g., a C 1-15 or C 1-10 amine group).
- Z is a C 1-20 amide group (e.g., a C 1-15 or C 1-10 amide group).
- Z is a C 1-20 ether group (e.g., a C 1-15 or C 1-10 ether group, or a C 1-20 , C 1-15 or C 1-10 polyether group).
- Z is a C 1-20 ester group (e.g., a C 1-15 or C 1-10 ester group).
- Z is a C 1-20 thioether group (e.g., a C 1-15 or C 1-10 thioether group, or a C 1-20 , C 1-15 or C 1-10 polythioether group).
- Z includes a first functional group, A 1 , which connects Z to X.
- a 1 is selected from:
- a 1 is a C 6-10 arylene group or a C 5-10 heteroarylene group.
- a 1 is a C 5-10 heteroarylene group.
- a 1 is a group obtained by CLICK chemistry.
- a 1 is a group obtained by 1,3-dipolar cycloaddition.
- a 1 is a 1,2,3-triazole group.
- a 1 may be a group having the following formula: wherein the wavy line indicates the point of attachment to the rest of Z, and the asterisk * indicates the carbon to which X is attached.
- Such a group can be obtained through Huisgen cycloaddition between an azide group and an alkyne group.
- Z includes a second functional group, A 2 , which connects Z to Sac 1 (when n is 0) or Sac N (when n>0).
- a 2 is selected from
- Z is a moiety having the following formula: wherein:
- d is 3 and e is 5.
- the core moiety X is a group to which the sialic-acid containing recognition groups, Y, are attached.
- X is a C 1-30 group to which Y is attached (e.g., a C 1-20 group, or a C 1-15 group).
- X is a C 1-30 alkylene group (e.g., a C 1-20 alkylene group or a C 1-15 alkylene group).
- X is a C 1-30 alkenylene group, the group having 1 to 3 carbon-carbon double bonds (e.g., a C 1-20 alkenylene group or a C 1-15 alkenylene group).
- X is a C 1-30 alkynylene group, the group having 1 to 3 carbon-carbon triple bonds (e.g., a C 1-20 alkynylene group or a C 1-15 alkynylene group).
- X is a C 1-30 amine group (e.g., a C 1-20 or C 1-15 amine group).
- X is a C 1-30 amide group (e.g., a C 1-20 or C 1-15 amide group).
- X is a C 1-30 ether group (e.g., a C 1-20 or C 1-15 ether group, or a C 1-30 , C 1-20 or C 1-15 polyether group).
- X is a C 1-30 ester group (e.g., a C 1-12 or C 1-15 ester group).
- X is a C 1-30 thioether group (e.g., a C 1-20 or C 1-15 thioether group, or a C 1-30 , C 1-20 or C 1-15 polythioether group).
- heteroatoms e.g, O, S, N
- aromatic rings e.g., benzene, pyridine or 1,2,3-triazole
- three Y recognition groups are linked to a single carbon atom on the core moiety, as shown in the following formula: wherein: X L1 , X L2 and X L3 are linking groups, and the wavy line indicates the point of attachment to the rest of X.
- X L1 , X L2 and X L3 are, R X1 OR X2 , R X1 NHR X2 or R X1 SR X2 , where R X1 is a bond or C 1-6 alkylene and R X2 is a bond or C 1-6 alkylene.
- three Y recognition groups are linked (e.g. via X L groups) to the same single multivalent carbon atom ("tripodal core") of the core moiety, and the anomeric centre of the sialic acid moiety is separated from said single carbon atom by 20 to 30 bond lengths (e.g., 22 to 25 bond lengths).
- three Y recognition groups are linked to the single carbon atom on the core moiety, and the anomeric centre of the sialic acid moiety is separated from said single carbon atom by 1.5 to 3 nm (e.g., 2 to 2.5 nm).
- X is a moiety having the following formula: wherein:
- f is 4 and g is 3.
- X L1 , X L2 and X L3 are -CH 2 -O-CH 2 - or -CH 2 -S-CH 2 -.
- X is a moiety of the following formula:
- the linking moiety L comprises a functional group which attaches the core moiety X to the nanoparticle.
- L is a sulphur atom, S, which binds to the nanoparticle, i.e., a moiety of the following formula: wherein the wavy line indicates the point of attachment to X and the asterisk * indicates the point of attached to nanoparticle O.
- L is derived from a 1,2-dithiolane.
- L is a moiety of the following formula: wherein the wavy line indicates the point of attachment to X and the asterisk * indicates the point of attached to nanoparticle O.
- L may be derived from the 1,2-dithiolane group of thioctic acid (lipoic acid) or thioctic acid amide, or derivatives thereof.
- the conjugate is of formula (I): wherein:
- O in formula (I) is a gold nanoparticle.
- n 0.
- d is 3 and e is 5.
- f is 5 and g is 4.
- X L1 , X L2 and X L3 are - CH 2 -O-CH 2 -.
- the conjugate additionally comprises polyethylene glycol, preferably at an HB to PEG ratio of 25:75.
- Y has the following formula: where the asterisk (*) indicates the carbon atom to which X is attached.
- the conjugate has the following formula:
- glycoconjugate ligand compounds which can be attached to a nanoparticle to make nanoparticle probes, and precursors of such compounds.
- glycoconjugate ligand compound of the following formula: wherein:
- the linking moiety L* comprises a functional group which can attach the core moiety X to a nanoparticle.
- L* may be a thiol group (e.g., SH).
- a reference to carboxylic acid also includes the anionic (carboxylate) form (-COO - ), a salt or solvate thereof, as well as conventional protected forms.
- a reference to an amino group includes the protonated form (-N + HR a R b ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group.
- a reference to a hydroxyl group also includes the anionic form (-O-), a salt or solvate thereof, as well as conventional protected forms.
- nanoparticle probes described herein form one aspect of the present invention, as do kits comprising them.
- Glycoconjugates as described herein may be prepared using conventional methods known in the art, or by adapting conventional methods known in the art in conventional ways.
- Synthesis of sialic acid moieties where R C4 is -NR N4 R N5 can be made using, for example, the methods described in Vonitzstein [33] .
- the method of making a glycoconjugate may comprise:
- a probe as described herein may be provided by:
- the step of creating group Y may include the step of reacting the monosaccharide units with a spacer moiety (Z).
- Step (i) may involves forming an ⁇ -2,3 glycosidic bond between sialic acid and one of the one or more monosaccharide units.
- Step (i) may involves forming an ⁇ -2,6 glycosidic bond between sialic acid and one of the one or more monosaccharide units.
- the step of attaching three or more glycoconjugate ligands to a core moiety may include carrying out a 1,3 dipolar cycloaddition.
- the 1,3 dipolar cycloaddition may involve cycloaddition of a propargyl-ether-moiety and an azide moiety.
- Ranges are often expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent "about,” it will be understood that the particular value forms another embodiment.
- Example 1 - alyconanoparticles presenting a trivalent ⁇ 2,6-thio-linked sialic acid can detect strains of human influenza within 30 mins in a simple colorimetric assay.
- FIG. 1 A schematic representation of the aggregation of the glyconanoparticles in the presence of the influenza virus is shown schematically in Figure 1 .
- the particles were used to detect the X31 virus from allantoic fluid (AF) at clinically relevant concentrations.
- AF allantoic fluid
- the ⁇ 2,6-binding trivalent sialic acid glyconanoparticles were shown to specifically detect human rather than avian influenza virus.
- the synthesis of the monovalent ligand 3 is detailed in Scheme 2.
- the aliphatic side chain of the alkyl thioglycoside of monovalent ligand 3 was synthesised starting from N- Boc-2,2'-(ethylenedioxy)bis(ethylamine) ( 11 ) prepared from the corresponding diamine following a published procedure. [25]
- the mono- N -Boc-protected diamine 11 was then reacted with iodoacetic anhydride to give the corresponding iodoacetamide 12 in 70 % yield.
- Compound 12 was then used for the formation of the thioglycoside 15.
- the synthesis of monovalent ligand 3 started with the known ⁇ -thioacetate 13 [26,27] .
- the UV-Vis spectrum in Figure 2a highlights the broadening of the surface plasmon absorption band of the 25:75 ratio trivalent ligand 1 :PEG gold nanoparticles indicating significant interaction with the influenza virus.
- the same experiment was performed using gold nanoparticles functionalized with different ratios of monovalent ligand 3 :PEG ligand 2 (50:50, 25:75, 10:90, 5:95 and 2:98).
- the results obtained suggest that a 25:75 ratio of the monovalent ligand 3 :PEG was also the optimum ligand density ( Figure 8 ).
- the optimized glyconanoparticles were used to colorimetrically detect increasing concentrations of the X31 influenza virus.
- Figure 2b upon addition of the human influenza virus X31 the surface plasmon absorption band red-shifted (from 525 to 536 nm) and decreased in intensity with increasing concentration of the virus ( Figure 2b and Figure 9a ).
- the results suggest that the influenza virus induces aggregation of the glyconanoparticles as schematically shown in Figure 1 .
- the aggregation of the optimized glyconanoparticles was spectroscopically measured 30 min following addition of increasing virus concentration. Changes of the surface plasmon absorption band due to the addition of the virus led to changes of solution color, from the initial deep red to lighter red ( Figure 9b ).
- Trivalent ligand 1 was synthesised containing three ⁇ 2,6-thio-linked sialic acids. Human influenza virus binds preferentially to ⁇ 2,6 residues while avian influenza virus binds to ⁇ 2,3 residues. [14] Consequently, the optimized glyconanoparticles should not aggregate in the presence of avian influenza virus.
- a thiolated trivalent ⁇ 2,6-thio-linked sialic acid derivative to functionalize gold nanoparticles.
- the optimised glyconanoparticles consist of the thiolated trivalent ⁇ 2,6-thio-linked sialic acid derivative and a thiolated PEG derivative self-assembled onto the gold surface in a 25:75 ratio. These glyconanoparticles were used for the plasmonic detection of influenza virus.
- the trivalent ligand 1:PEG (25:75) functionalized gold nanoparticles were used to detect the human influenza virus X31 (H3N2) within 30 min. Non-purified, influenza virus in allantoic fluid was successfully detected by the functionalized nanoparticles.
- a comparison between the trivalent and a monovalent ⁇ 2,6-thio-linked sialic acid functionalized nanoparticles confirmed that more rapid results, with greater sensitivity, were achieved using the trivalent ligand for the detection of the X31 virus.
- the trivalent ligand 1 :PEG (25:75) functionalized gold nanoparticles were able to discriminate between human ( ⁇ 2,6 binding) and avian ( ⁇ 2,3 binding) influenza. Since the dominant strain of human influenza varies seasonally, and with the possible threat of influenza virus crossing between animal species and thereby potentially initiating a pandemic, the ability to distinguish between human and avian influenza virus strains is exceptionally important.
- the synthesis of a trivalent ⁇ 2,6-thio-linked sialic acid derivative to functionalize gold nanoparticles provides an innovative bioassay for the specific recognition and detection of influenza virus strains in clinical samples.
- N -Boc aminopentanoic acid (valeric acid) was purchased from Sigma Aldrich. TLC was performed on precoated silica plates (Merck 60 F254, 0.25 mm) containing a fluorescence indicator.
- NMR spectra were recorded on a Bruker spectrometer: 1 H NMR spectra recorded at 400 MHz were referenced to ⁇ H 7.26 for CDCl 3 or ⁇ H 3.34 for CD 3 OD; 13 C NMR spectra recorded at 100 MHz were referenced to ⁇ c 77.0 for CDCl 3 or ⁇ C 49.05 for CD 3 OD. Chemical shifts of NMR signals recorded in D 2 O are reported with respect to the methyl resonance of internal acetone at ⁇ H 2.22 ppm and ⁇ C 30.89 ppm, respectively. Assignments were made with the aid of COSY and HSQC experiments. Multiplicity of signals in 13 C NMR spectra was determined from HSQC spectra.
- This oil was taken up in dry DMF (0.5 mL) and added to a mixture of commercial N -Boc aminopentanoic acid (86 mg, 0.4 mmol), HATU (2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate) (0.2 g, 0.5 mmol), N -methylmorpholine (0.1 g, 1 mmol) in DMF (1 mL). The reaction was stirred at room temperature overnight, the DMF removed in vacuo, the resulting residue was taken up in CH 2 Cl 2 (25 mL), washed with water, dried (MgSO 4 ) and concentrated to dryness.
- UV-Visible spectra were recorded using a Perkin Elmer Lambda 25 UV-Vis spectrometer at room temperature. Quartz cuvettes with a 1 cm path length were used. Transmission electron microscopy (TEM) images were obtained using a Jeol 2000EX transmission electron microscope, operating at 200 KV, by depositing samples on holey carbon film 300 mesh copper grids from Agar Scientific, UK.
- TEM Transmission electron microscopy
- Water soluble gold nanoparticles were prepared via the citrate reduction method reported by Enüstün and Turkevich. [5] Briefly, aqueous solutions of HAuCl 4 ⁇ 3H 2 O (12.5 mg, 32 ⁇ mol, in 100 mL) and sodium citrate tribasic dihydrate (50 mg, 168 ⁇ mol, in 50 mL) were prepared and heated to 60 °C. The sodium citrate solution was rapidly added to the gold solution while stirring vigorously. The temperature was increased to 85 °C and the solution was stirred for 2.5 h. A clear red gold nanoparticle solution was obtained that was cooled to room temperature and filtered through a Miller GP syringe driven filter unit (0.22 ⁇ m). The particle concentration in the citrate stabilized gold nanoparticles solution was approximately 3 nM.
- Gold nanoparticles were functionalized with varying ratios of trivalent ligand 1 and PEG ligand 2. Varying molar ratios of trivalent ligand 1 and PEG based ligand 2 ( Table 4 ) were added to aliquots of freshly prepared gold nanoparticles (17 mL) and stirred for 60 h at room temperature to ensure self-assembly of the ligands onto the gold surface. The nanoparticle solution was centrifuged using Amicon Ultra-4 centrifugal filter units (10,000 MW cut-off) in a Sorvall Legend RT centrifuge for 10 min at 4,000xg to remove the excess trivalent ligand 1 and PEG ligand 2.
- Gold nanoparticles were functionalized with varying ratios of monovalent ligand 3 and PEG ligand 2. Varying molar ratios of monovalent ligand 3 and PEG based ligand 2 ( Table 5 ) were added to aliquots of freshly prepared gold nanoparticles (17 mL) and stirred for 60 h at room temperature to ensure self-assembly of the ligands onto the gold surface. Excess ligands were removed as previously described for gold nanoparticles functionalized with trivalent ligand 1 and PEG ligand 2. Table 5. Molar ratios of monovalent ligand 3 and PEG ligand 2 added to the gold nanoparticles.
- PEG ligand 2 (30.2 nmol) was added to a freshly prepared citrate stabilized gold nanoparticles solution (17 mL). The solution was stirred for 60 h at room temperature to ensure self-assembly of the ligand onto the gold surface. Excess ligands were removed as previously described for gold nanoparticles functionalized with trivalent ligand 1 and PEG ligand 2.
- X31 virus (H3N2) (2.55 ⁇ g/mL) was added to a sample of each of the synthesized gold nanoparticles including: citrate coated gold nanoparticles; trivalent ligand 1 :PEG functionalized gold nanoparticles (50:50, 25:75, 10:90, 5:95 and 2:98); and monovalent ligand 3 :PEG functionalized gold nanoparticles (50:50, 25:75, 10:90, 5:95 and 2:98).
- the samples were stirred at room temperature and the UV-Vis spectrum was recorded before addition of the virus and 0, 15, 30, 60 and 240 min after addition of the virus.
- the UV-Vis spectrum of the sample was measured before addition of the AF X31 virus and 30 min after addition of the corresponding volume.
- the same measurements were repeated although adding increasing volumes of Tris buffer (from 0 to 47.1 ⁇ L) to a sample of trivalent ligand 1 :PEG (25:75) functionalized gold nanoparticles (1000 ⁇ L).
- avian RG14 virus H5N1
- H5N1 avian RG14 virus
- Each virus (6.8 ⁇ g/mL) was added to a sample of trivalent ligand 1 :PEG (25:75) functionalized gold nanoparticles.
- the UV-Vis spectrum of each sample was measured after stirring the samples for 6 days at room temperature.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
- Sonde nanoparticulaire comprenant une pluralité de ligands glycoconjugués,
chaque ligand glycoconjugué (GL) ayant une pluralité de groupes de reconnaissance contenant de l'acide sialique (Y) couplés à la nanoparticule via un coeur multivalent (X),
dans laquelle le coeur multivalent (X) est un coeur trivalent, en conséquence de quoi il y a 3 groupes de reconnaissance par ligand,
dans laquelle les groupes de reconnaissance sur le bioconjugué se lient spécifiquement à l'hémagglutinine sur le virus grippal cible,
laquelle sonde a au moins un autre type de ligand lié à la nanoparticule, dans laquelle l'autre type de ligand est un polyéthylèneglycol (PEG) qui ne se lie pas spécifiquement à un virus grippal, dans laquelle chaque groupe de reconnaissance se termine par l'α-anomère d'un fragment d'acide sialique, et le fragment d'acide sialique est lié à un monosaccharide par l'intermédiaire soit :(i) d'une liaison 2,6-glycosidique, auquel cas le virus grippal cible est un virus grippal humain, lequel virus grippal humain est éventuellement un virus H3, soit(ii) d'une liaison 2,3-glycosidique, et le virus grippal cible est un virus grippal aviaire,et dans laquelle le rapport molaire du ligand glycoconjugué à l'autre ligand est compris entre 10/90 et 90/10. - Sonde selon la revendication 1, dans laquelle le fragment acide sialique et le monosaccharide sont liés par liaison thio, et dans laquelle le monosaccharide est éventuellement le galactose.
- Sonde selon l'une quelconque des revendications 1 et 2, dans laquelle l'autre ligand est un PEG thiolaté.
- Sonde selon l'une quelconque des revendications 1 à 3, dans laquelle le rapport molaire du ligand glycoconjugué à l'autre ligand est compris entre 15/85 et 35/65, mieux encore entre 20/80 et 30/70.
- Sonde selon l'une quelconque des revendications 1 à 4, dans laquelle le rapport molaire du ligand glycoconjugué à l'autre ligand est d'environ 25/75.
- Sonde selon l'une quelconque des revendications 1 à 5, dans laquelle chaque sonde nanoparticulaire comprend un nombre moyen de molécules de ligand glycoconjugué égal à ou d'au moins 5, 10, 25, 50, 100 ou 200 par nanoparticule, et éventuellement la nanoparticule est une nanoparticule d'or, qui a éventuellement un diamètre de 10 à environ 30 nm.
- Sonde selon la revendication 7, dans laquelle(i) L est une liaison thiol, et/ou(ii) X comprend un atome de carbone multivalent auquel trois groupes de reconnaissance Y sont liés via des groupes XL :
et où XL1, XL2 et XL3 sont -CH2-O-CH2-, et/ou(iii) Y comprend un fragment écarteur (Z) qui connecte le fragment contenant de l'acide sialique au groupe de coeur X,
où Z comprend un groupe alkylène ou alcénylène qui contient éventuellement une ou plusieurs liaisons amine, amide, éther, ester ou thioester, et est éventuellement interrompu par un ou plusieurs hétéroatomes et/ou cycles aromatiques, et où Z est éventuellement un fragment de formule suivante : - Procédé pour détecter spécifiquement un virus grippal cible dans un échantillon, lequel procédé comprend :(a) l'obtention d'une sonde nanoparticulaire selon l'une quelconque des revendications 1 à 9 ;(b) la mise en contact de la sonde nanoparticulaire et de l'échantillon dans des conditions efficaces pour lier spécifiquement l'hémagglutinine du virus grippal cible aux groupes de reconnaissance, dans laquelle ladite liaison spécifique génère un signal plasmonique détectable qui est spécifique du virus grippal ;(c) la détection du signal généré dans l'étape b).
- Procédé selon la revendication 10, dans lequel le signal détectable est un changement de couleur qui est observable à l'oeil nu, éventuellement dans lequel ladite liaison spécifique dans l'étape (b) provoque une agrégation d'une suspension aqueuse des nanoparticules, et dans lequel ladite agrégation génère ou contribue au signal plasmonique détectable.
- Trousse comprenant(i) une sonde nanoparticulaire selon l'une quelconque des revendications 1 à 9, ou(ii) une composition de détection de virus grippal comprenant une suspension aqueuse de sondes nanoparticulaires selon les revendications 1 à 9,dans chaque cas éventuellement avec des instructions d'utilisation pour la mise en oeuvre d'un procédé tel que défini dans la revendication 10 ou la revendication 11.
- Procédé pour préparer une sonde nanoparticulaire, lequel procédé comprend :(a) la préparation d'un composé ligand glycoconjugué tel que défini dans l'une quelconque des revendications 1 à 9 par :(i) création d'un groupe de reconnaissance contenant de l'acide sialique (Y) pour la liaison de HA par rattachement d'un ou plusieurs motifs monosaccharidiques à un acide sialique ;(ii) rattachement de trois groupes de reconnaissance contenant de l'acide sialique (Y) à un fragment de coeur (X) comprenant un fragment de liaison (L) ;(b) le rattachement du composé ligand glycoconjugué à une nanoparticule, via un fragment lieur (L).
- Procédé selon la revendication 13, dans lequel l'étape de création du groupe Y comprend l'étape de réaction des motifs monosaccharidiques avec un fragment écarteur (Z).
- Procédé selon la revendication 13 ou la revendication 14, dans lequel l'étape de rattachement de trois groupes de reconnaissance (Y) au fragment de coeur comprend la mise en oeuvre d'une cycloaddition 1,3-dipolaire, et dans lequel la cycloaddition 1,3-bipolaire met éventuellement en jeu la cycloaddition d'un fragment propargyl-éther et d'un fragment azoture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1313201.4A GB201313201D0 (en) | 2013-07-24 | 2013-07-24 | Virus Detection |
PCT/GB2014/052026 WO2015011441A1 (fr) | 2013-07-24 | 2014-07-03 | Détection de virus |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3024841A1 EP3024841A1 (fr) | 2016-06-01 |
EP3024841B1 true EP3024841B1 (fr) | 2018-11-21 |
EP3024841B8 EP3024841B8 (fr) | 2019-02-27 |
Family
ID=49119197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14736939.1A Active EP3024841B8 (fr) | 2013-07-24 | 2014-07-03 | Détection de virus |
Country Status (6)
Country | Link |
---|---|
US (1) | US10174069B2 (fr) |
EP (1) | EP3024841B8 (fr) |
CN (1) | CN105658657B (fr) |
CA (1) | CA2918674C (fr) |
GB (1) | GB201313201D0 (fr) |
WO (1) | WO2015011441A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
MX2018005999A (es) * | 2015-11-20 | 2018-11-22 | Australian Biomedical Co Pty Ltd | Compuestos para aplicaciones medicinales. |
CN106589014B (zh) * | 2016-12-05 | 2019-03-08 | 中国科学院微生物研究所 | 唾液酸寡糖-磁纳米粒子及其制备方法与应用 |
US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
CN111698995A (zh) * | 2018-02-17 | 2020-09-22 | 箭头药业股份有限公司 | 三炔连接剂和使用方法 |
US12065458B2 (en) | 2018-02-17 | 2024-08-20 | Arrowhead Pharmaceuticals, Inc. | Trialkyne linking agents and methods of use |
WO2022094932A1 (fr) * | 2020-11-06 | 2022-05-12 | 深圳先进技术研究院 | Bandelette réactive de détection de nouveau coronavirus, et son procédé de préparation et d'utilisation |
WO2022094912A1 (fr) * | 2020-11-06 | 2022-05-12 | 深圳先进技术研究院 | Sonde biologique, son procédé de fabrication et son application |
CN113984747B (zh) * | 2021-10-21 | 2024-04-05 | 南京理工大学 | 一种金纳米阵列表面修饰唾液酸的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080194801A1 (en) * | 2007-02-14 | 2008-08-14 | Swanson Basil I | Robust multidentate ligands for diagnosis and anti-viral drugs for influenza and related viruses |
-
2013
- 2013-07-24 GB GBGB1313201.4A patent/GB201313201D0/en not_active Ceased
-
2014
- 2014-07-03 EP EP14736939.1A patent/EP3024841B8/fr active Active
- 2014-07-03 CA CA2918674A patent/CA2918674C/fr not_active Expired - Fee Related
- 2014-07-03 US US14/906,436 patent/US10174069B2/en active Active
- 2014-07-03 WO PCT/GB2014/052026 patent/WO2015011441A1/fr active Application Filing
- 2014-07-03 CN CN201480052170.2A patent/CN105658657B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
WO2015011441A1 (fr) | 2015-01-29 |
EP3024841B8 (fr) | 2019-02-27 |
US10174069B2 (en) | 2019-01-08 |
EP3024841A1 (fr) | 2016-06-01 |
CA2918674C (fr) | 2021-06-15 |
CN105658657B (zh) | 2020-03-03 |
GB201313201D0 (en) | 2013-09-04 |
CA2918674A1 (fr) | 2015-01-29 |
CN105658657A (zh) | 2016-06-08 |
US20160185814A1 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3024841B1 (fr) | Détection de virus | |
Hatano et al. | Carbosilane glycodendrimers | |
He et al. | Carbohydrate CuAAC click chemistry for therapy and diagnosis | |
KR101050774B1 (ko) | 당 사슬-포착 분자로 당 사슬을 정제/농축하는 방법 및 당사슬 구조의 분석법 | |
He et al. | Fluorescent glycoprobes: a sweet addition for improved sensing | |
Kato et al. | Development of tetraphenylethylene-based fluorescent oligosaccharide probes for detection of influenza virus | |
JP2005519627A (ja) | バイオコンジュゲート‐ナノ粒子プローブ | |
Galante et al. | Glycoclusters presenting lactose on calix [4] arene cores display trypanocidal activity | |
US20060057658A1 (en) | Labeled substrate conjugates for identifying enzyme inhibitors | |
Oka et al. | Syntheses and biological evaluations of carbosilane dendrimers uniformly functionalized with sialyl α (2→ 3) lactose moieties as inhibitors for human influenza viruses | |
JP2011153096A (ja) | 蛍光性糖鎖プローブ | |
WO2008100553A1 (fr) | Ligands multidentates robustes de diagnostics et médicaments antiviraux contre la grippe et des virus associés | |
Kumari et al. | Synthetic assembly of novel avidin-biotin-GlcNAc (ABG) complex as an attractive bio-probe and its interaction with wheat germ agglutinin (WGA) | |
CN107917903A (zh) | 糖基低维材料在甲型流感病毒荧光检测中的应用 | |
CN115572335B (zh) | 一种用于甲醛监测的壳聚糖基荧光探针及其制备方法和应用 | |
CN108623711A (zh) | 阿魏酸-环糊精共价偶联化合物及其制备方法和应用 | |
US8513394B2 (en) | Saccharide fluorescent substrates, preparation method and uses thereof | |
Montenegro et al. | Multivalent assembly of a pyrene functionalized thio-N-acetylglucosamine: Synthesis, spectroscopic and WGA binding studies | |
CN110872335B (zh) | 唾液酸寡糖-量子点缀合物、其制备方法及用途 | |
CA2071915A1 (fr) | Agent antiviral | |
CN102952207A (zh) | 6-(1-甲基-β-咔啉-3-羧酸乙酰基)-6-脱氧-β-环糊精及其与阿霉素超分子包结配合物的制备和应用 | |
KR100670948B1 (ko) | 쿠커비투릴 유도체 단일 분자에 공유결합된 탄수화물다량체 | |
keung Chan | Synthesis And Functionality Study of Novel Biomimetic N-glycan Polymers | |
WO2005082918A1 (fr) | Glycolipide en forme de bola polymérisable, agrégat tubulaire de celui-ci et polymère de celui-ci | |
JPH06247995A (ja) | 新規なシアリル(α2−6)ラクトテトラオシルセラミド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170207 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180524 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20181011 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: ICENI DIAGNOSTICS LIMITED |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1067389 Country of ref document: AT Kind code of ref document: T Effective date: 20181215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014036467 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20181121 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1067389 Country of ref document: AT Kind code of ref document: T Effective date: 20181121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190221 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190321 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190221 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190222 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190321 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014036467 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190731 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190731 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140703 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181121 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230623 Year of fee payment: 10 Ref country code: FR Payment date: 20230623 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230620 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230623 Year of fee payment: 10 |